

JOINT PRESS RELEASE
FOR IMMEDIATE RELEASE

**PHARMANIAGA ASSURES PAYMENT ISSUES WILL BE
RESOLVED EARLIEST BY END OF APRIL**

SHAH ALAM, 4 April 2023 - Pharmaniaga Berhad (Pharmaniaga) assures all vendors and suppliers that the Group is confident the current delay in payments will be resolved and normalised earliest by the end of the month.

In a fruitful meeting held yesterday with the Pharmaceutical Association of Malaysia (PhAMA), Pharmaniaga addressed the association's concerns regarding its Practice Note 17 (PN17) status and issues pertaining to delays in payment to its suppliers.

The Company briefed that most of its obligations to the suppliers have since been cleared, and it will continue to honour all commitments to ensure patients' access to medicine remains uninterrupted and continues to be intact.

Pharmaniaga also explained that its core business activities in research & development, manufacturing, logistics & distribution, sales & marketing as well as Indonesian operations are proceeding as usual and not affected by the current situation.

Certain moving forward action plans have been agreed upon by both parties, which include more proactive engagements in addressing operational issues with regards to the medicines and non-medicines supplies to the Government and private healthcare facilities. Both parties will also work closer towards creating a more consistent and predictable ecosystem that encourages stable operations.

Amongst present during the meeting were PhAMA's Board Members Tan Sri Ariffin Yusuf and Louis-George Lasonnery, Executive Director Chan Li Jin, and representatives from Zuellig Pharma, Roche Malaysia, Lundbeck Malaysia, Novartis Malaysia, Sanofi Malaysia, DKSH Holdings Malaysia and Novo Nordisk Malaysia.

Meanwhile, Pharmaniaga was represented by Deputy Chief Executive Officer Zulkifli Jafar and Commercial Director Zulhazri Razali.

-END-

About Pharmaniaga Berhad (Pharmaniaga)

Pharmaniaga is the leading pharmaceutical company of Boustead Holdings Berhad Group of Companies, which together with the Armed Forces Fund Board, are the major shareholders of Pharmaniaga. Listed on the Main Market of Bursa Malaysia Securities Berhad, Pharmaniaga's core businesses are generic pharmaceuticals manufacturing; research and development; marketing and sales; warehousing and distribution of pharmaceutical and medical products; supply, trading and installation of medical and hospital equipment as well as community pharmacy.

With a vision to be the premier Malaysian pharmaceutical company, Pharmaniaga is guided by its philosophy of 'Do It Right Always' and empowered by its motto of Passion for Patients. Strengthened by nine manufacturing plants, nationwide logistics and distribution in Malaysia and Indonesia as well as products registered in 15 countries, Pharmaniaga is positioned to be a regional player in the international pharmaceutical arena. For more information, please log on to <https://pharmaniaga.com/>.

Issued for Pharmaniaga Group by Corporate Communications Department, Pharmaniaga Berhad. For media enquiries, please contact Dato' Zuhri Iskandar Kamarzaman, CARE and Media Director of Pharmaniaga Berhad at 03-3342 999 ext 434 or by email zuhri@pharmaniaga.com.